Novartis strengthens Aimovig position with new data

1 July 2019

Despite competition in the anti-CGRP migraine therapy space, Swiss pharma giant Novartis’ (NOVN: VX) Aimovig (erenumab) has become the most-prescribed in the since its launch last year.

Others fighting for market share in the CGRP inhibitor space include Teva Pharmaceutical Industries (NYSE: TEVA) and Eli Lilly (NYSE: LLY), but Novartis has done its chances of hanging on to top spot no harm with new long-term data.

The findings, presented at the European Academy of Neurology annual meeting in Oslo, Norway, showed that Aimovig (erenumab) 70mg and 140mg significantly reduced monthly migraine days and migraine-specific medication days for episodic migraine patients who have previously struggled to find effective and tolerable preventive therapies specifically designed for migraine prevention.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK